Drug Information

Drug (ID: DG01810) and It's Reported Resistant Information

• Name: Tanshinone IIA
• Synonyms: Tanshinone IIA; 568-72-9; Tanshinone II; Dan Shen Ketone; Tanshinone B; Tanshinon II; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione; UNII-4GPC9FQG6L; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione; Phenanthro[1,2-b]furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; C19H18O3; 4GPC9FQG6L; MLS001048863; MFCD00238692; NSC686519; SMR000387068; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione; Phenanthro(1,2-b)furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; tanshinone II A; SR-01000758926; NSC 686518; tanshinone-IIA; HSDB 8104; Tanshinone centoA; Tanshinone 2-A; Tanshinone Iia ,(S); BSPBio_001597; BSPBio_002426; KBioGR_000317; KBioSS_000317; MLS006011834; SPECTRUM1505824; CHEMBL187266; cid_164676; SCHEMBL2026738; Tanshinone IIA (Tanshinone B); BDBM83922; KBio2_000317; KBio2_002885; KBio2_005453; KBio3_000633; KBio3_000634; DTXSID60205352; CHEBI:108595; Bio2_000317; Bio2_000797; HMS1361P19; HMS1791P19; HMS1989P19; HMS2089H08; HMS2270D15; HMS3402P19; HMS3656C11; NP474; BCP28199; HY-N0135; Tanshinone IIA, analytical standard; ZINC1650576; BBL028449; s2365; STK801917; Tanshinone IIA, >=97% (HPLC); AKOS004120032; AC-1440; CCG-207955; CCG-208275; NSC-686519; IDI1_034067; NCGC00095709-01; NCGC00095709-02; NCGC00095709-03; NCGC00095709-04; NCGC00095709-05; NCGC00095709-06; NCGC00095709-08; AS-16136; NCI60_031209; S594; NCGC00095709-02!TANSHINONE IIA; FT-0652880; N1846; SW220025-1; T2987; 568T729; A831217; Q-100654; SR-01000758926-2; SR-01000758926-4; SR-01000758926-5; BRD-K00141480-001-03-0; Q27187517; Phenanthro[1,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; Tanshinone IIA, European Pharmacopoeia (EP) Reference Standard; Tanshinone IIA, United States Pharmacopeia (USP) Reference Standard; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione #; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-quinone; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione; 6,7,8,9-Tetrahydro-1,6,6-trimethylphenanthro[1,2-b]furan-10,11-dione
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (2 diseases)
  Cataract [ICD-11: 9B10]; [1]
  Myocardial infarction [ICD-11: BA41]; [2]
• Target: .; NOUNIPROTAC; [1]
• IsoSMILES: CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C
• InChI: InChI=1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3
• InChIKey: HYXITZLLTYIPOF-UHFFFAOYSA-N
• PubChem CID: 164676

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-09: Visual system diseases

Cataract [ICD-11: 9B10]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: CDKN2B antisense RNA 1 (CDKN2B-AS1) [1]

• Molecule Alteration: Up-regulation; Expression
• Resistant Disease: Age-related nuclear cataract [ICD-11: 9B10.0Y]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SRA01/04 cells; Eye; Homo sapiens (Human); CVCL_7157
• Experiment for Molecule Alteration: Mimic assay; qRT-PCR; Knockdown assay; Western bloting analysis
• Experiment for Drug Resistance: CCK8 assay; Flow cytometry assay; Carboxy-H2DCFDA assay
• Mechanism Description: Tanshinone IIA protects lens epithelial cells from H2 O 2 -induced injury by upregulation of LncRNA ANRIL.

ICD-11: Circulatory system diseases

Myocardial infarction [ICD-11: BA41]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (AK003290) [2]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Acute myocardial infarction [ICD-11: BA41.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: H9C2 cells; Ovary; Cricetulus griseus (Chinese hamster); CVCL_A0TS
• In Vivo Model: I/R female C57BL/6 mice model; Mus musculus
• Experiment for Molecule Alteration: Knockdown assay; qRT-PCR; Western bloting analysis; RNA pull down assay; FISH assay; Luciferase assay
• Experiment for Drug Resistance: Flow cytometry assay; LDH and MDA detection assay; ROS detection assay; Dual-Luciferase assay
• Mechanism Description: TSA exerts the protective role against H/R induced apoptosis, oxidative and MMP loss of cardiomyocytes via regulating AK003290 and miR-124-5p signaling.

References

• Ref 1: Tanshinone IIA protects lens epithelial cells from H(2) O (2) -induced injury by upregulation of lncRNA ANRILJ Cell Physiol. 2019 Jan 30. doi: 10.1002/jcp.28189. Online ahead of print.
• Ref 2: Tanshinone IIA alleviates hypoxia/reoxygenation induced cardiomyocyte injury via lncRNA AK003290/miR-124-5p signalingBMC Mol Cell Biol. 2020 Mar 27;21(1):20. doi: 10.1186/s12860-020-00264-3.